Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
(WorldNews Asia)

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 - BOTHELL, Wash. and TOKYO, September 16, 2019 - Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., `Astellas`) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License...